Saturday, July 11, 2026

biotech · Immune Thrombocytopenia

Principia Biopharma

Principia Biopharma clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

South San Francisco, USA HQ
2008 Founded
16 Employees
NMPA registrant Type
Company details
Status
Public
HQ
South San Francisco, USA
Founded
2008
Employees
16
Programs
1
Drugs
1
Patents
0
Intelligence · Clinical Programs

Principia Biopharma projects

1 ClinicalTrials.gov programs sponsored by Principia Biopharma.

Principia Biopharma has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Rilzabrutinib

    Principia Biopharma, a Sanofi Company

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Principia Biopharma have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.